Drug Profile
RDX 7675
Alternative Names: RDX 022; RDX 227675; RDX 7675Latest Information Update: 06 Dec 2017
Price :
$50
*
At a glance
- Originator Ardelyx
- Class Cardiovascular therapies; Polymers; Polystyrenes
- Mechanism of Action Binding agents; Potassium binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperkalaemia
Most Recent Events
- 21 Nov 2017 Ardelyx terminates a phase III trial in Hyperkalaemia in USA because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial(PO)
- 21 Nov 2017 Ardelyx terminates a phase II trial for Hyperkalaemia in USA because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial (PO) (NCT03018067)
- 21 Nov 2017 Ardelyx terminates a phase IIb trial for Hyperkalaemia in USA because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial (PO)